Actively Recruiting

Age: 18Years +
All Genders
ID00948116

Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing Coronary Revascularisation

Led by Barts & The London NHS Trust · Updated on 2024-12-10

250

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research focuses on patients with diabetes mellitus who have a higher risk of kidney failure after using dye during heart artery procedures like percutaneous coronary intervention (PCI). Diabetes significantly increases the chance of developing contrast induced nephropathy (CIN), which can raise mortality within one year. The study aims to find new biomarkers that detect CIN earlier than current methods, improving safety and outcomes for this high-risk group. The study observes diabetic patients with reduced kidney function (eGFR <60 ml/min) undergoing planned PCI. Blood and urine samples will be collected before the procedure, then at 2, 4, 8 to 12 hours, before discharge, and 3 days post-procedure. These samples will be analyzed to identify biomarkers that could predict CIN development within 72 hours after the procedure. Participants will follow their usual care during the hospital stay while providing additional blood and urine samples. Researchers will monitor creatinine levels and biomarker presence to assess kidney injury risk. The main outcome is defined as an increase in creatinine of 44 micromol/l or more within 72 hours after PCI. This observational study includes about 250 patients and aims to improve early diagnosis and treatment of CIN in diabetic patients undergoing coronary revascularization.

CONDITIONS

Brief Title

Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age greater than 18 years
  • Known diabetes mellitus or blood markers indicating probable diabetes
  • Reduced kidney function with eGFR less than 60 ml/min
  • Scheduled to undergo a percutaneous coronary intervention (PCI) procedure
  • Willing to provide additional blood and urine samples as required
  • Agrees to allow access to medical records for data collection
  • No history or signs of drug abuse
  • Able to understand and sign informed consent
  • Willing and able to follow study protocol requirements
Not Eligible

You will not qualify if you...

  • Cardiogenic shock
  • Pregnancy
  • Receiving renal replacement therapy such as dialysis or kidney transplant
  • Known significant infections like HIV, Hepatitis, or tuberculosis
  • Unable to give informed consent before the procedure

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants undergo a planned percutaneous coronary intervention (PCI) procedure as part of their routine care. Blood and urine samples are collected before the procedure and at multiple time points after the procedure to identify biomarkers for earlier prediction of acute kidney injury.

1 day with multiple sample collections before and after PCI

Long-term Monitoring

Duration - Up to 3 days post-procedure

Participants are monitored for the development of acute kidney injury for up to 72 hours after the PCI procedure through additional sample collections and medical record review.

Additional sample collections up to 3 days after PCI

Trial Site Locations

Total: 1 location

1

The London Chest Hospital

London, United Kingdom, E2 9JX

Actively Recruiting

Loading map...

Research Team

A

AKHIL KAPUR

K

KATIE QURESHI

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

"Smart Family Doctor" Assisted Comprehensive Management of S...

Post Coronary Artery Bypass Grafting

Actively Recruiting

1 location

A Randomized, Parallel, Open-label Clinical Study on the Bio...

Diabetes Mellitus

Actively Recruiting

1 location

An Open-Label, Single-Dose Study to Evaluate MK-2828 Pharmac...

Chronic Kidney Failure

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here